Predicting Chemotherapy Response in Lung Cancer
Author Information
Author(s): M. Volm, P. Drings, E.W. Hahn, J. Mattern
Primary Institution: German Cancer Research Center
Hypothesis
Can an in vitro test predict which stage III lung adenocarcinoma patients will benefit from chemotherapy?
Conclusion
The in vitro test successfully predicted that patients with sensitive tumors lived significantly longer than those with resistant tumors.
Supporting Evidence
- Patients with in vitro sensitive tumors had a median survival of 185 weeks.
- Patients with in vitro resistant tumors had a median survival of 31 weeks.
- There was a statistically significant positive correlation between adriamycin sensitivity and patient survival time.
Takeaway
Doctors can use a simple test to see if lung cancer patients will respond well to chemotherapy, helping them choose the best treatment.
Methodology
A tumor cell suspension from surgical specimens was treated with adriamycin, and the uptake of radioactive nucleic acid precursors was measured to determine sensitivity.
Limitations
The study had a small sample size and only used adriamycin to predict tumor response.
Participant Demographics
Patients were previously untreated with stage III lung adenocarcinomas, with a minimum follow-up of 5 years.
Statistical Information
P-Value
0.023
Statistical Significance
p=0.023
Want to read the original?
Access the complete publication on the publisher's website